FDA Biosimilar Approvals: Oncology, Immunology, and Bone Health Year in Review
Okay, here’s a breakdown of the references provided, formatted for clarity:
References:
- FDA Approves tocilizumab-anoh as a Biosimilar too Actemra. Ferruggia K. Pharmacy Times. Published online October 26, 2023. Accessed December 19, 2025. https://www.pharmacytimes.com/view/fda-approves-tocilizumab-anoh-as-a-biosimilar-to-actemra
- FDA Approves Celltrion’s Eydenzelt, Biosimilar to Aflibercept, to Treat Ocular Conditions. Ferruggia K. Pharmacy Times. October 10, 2025. Accessed December 19,2025.https://www.pharmacytimes.com/view/fda-approves-celltrion-s-eydenzelt-biosimilar-to-aflibercept-to-treat-ocular-conditions
- FDA Approves Poherdy, First Biosimilar to Perjeta, For H (The reference is incomplete, the full title is missing). McGovern G. Pharmacy Times.(Date missing).
Key Observations:
* All references are from Pharmacy Times.
* the dates of publication and access are provided.
* the references relate to FDA approvals of biosimilars.
* Reference #3 is incomplete.